NextCure, Inc. Form 8-K Summary
Business Context and Reporting Period
NextCure, Inc. (NXTC), a Delaware corporation, filed this Current Report on Form 8-K on December 19, 2025. The Company is an emerging growth company with its principal executive offices in Beltsville, Maryland. Its common stock trades on the Nasdaq Global Select Market.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a new financing arrangement.
Material Changes
On December 19, 2025, the Company entered into an At-The-Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC. Key terms include:
- Offering Size: Up to $14,500,000 in aggregate sales price of common stock.
- Agent Compensation: 3.0% of gross proceeds from shares sold.
- Sale Method: Shares may be sold via negotiated transactions or "at the market" offerings on the Nasdaq Global Select Market or other trading venues at prevailing market prices.
- Proceeds Usage: Net proceeds will be used for general corporate purposes, working capital, preclinical studies, clinical trials, and the advancement of product candidates.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance or updated operational outlook beyond the stated intent to fund clinical and preclinical activities. Actual sales under the ATM Agreement depend on market conditions, trading price, and capital needs determined by the Company. The Company has provided customary representations and indemnification to the Agent regarding liabilities under the Securities Act.
Investor Verification Checklist
- Verify the current trading price of NXTC common stock to assess potential dilution impact from the $14.5 million offering.
- Review the attached ATM Agreement (Exhibit 1.1) for specific termination rights and volume limitations.
- Confirm the Company's current cash runway and immediate capital requirements to gauge the urgency of the offering.
- Monitor future filings for actual sales volumes and proceeds generated under the ATM program.